Nine Square Therapeutics
Nine Square Therapeutics is focused on developing innovative small-molecule therapeutics for neurodegenerative diseases such as Parkinson's disease and ALS. By leveraging advanced computational chemistry, biophysics, and machine learning, the company aims to identify and optimize drug candidates targeting previously undruggable pathways. Founded in 2020, Nine Square is committed to reshaping the treatment landscape for debilitating conditions through a unique approach that combines experimental biology with computational modeling. The company is building a diversified portfolio of first-in-class drug candidates and has received significant funding to advance its research and development efforts.
Nine Square Therapeutics
Nine Square Therapeutics is focused on developing innovative small-molecule therapeutics for neurodegenerative diseases such as Parkinson's disease and ALS. By leveraging advanced computational chemistry, biophysics, and machine learning, the company aims to identify and optimize drug candidates targeting previously undruggable pathways. Founded in 2020, Nine Square is committed to reshaping the treatment landscape for debilitating conditions through a unique approach that combines experimental biology with computational modeling. The company is building a diversified portfolio of first-in-class drug candidates and has received significant funding to advance its research and development efforts.